- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Ligand id: 5297
View more information in the IUPHAR Pharmacology Education Project: zileuton
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|Approved drug?||Yes (FDA (1996))|
|International Nonproprietary Names|
|A-64077 | ZYFLO®|
|Zileuton is an orally active 5-LOX inhibitor.
The approved drug is a racemic mixture of R(+) and S(-) enantiomers (PubChem CID 10681296 and CID 10220327 respectively), which are both pharmacologically active. The structure shown here does not specify stereochemistry and represents the mixture.
The hepatotoxicity of zileuton is suggested to be due to the N-hydroxyurea group .
|CAS Registry No.||111406-87-2|
|GtoPdb PubChem SID||178101979|
|Search Google for chemical match using the InChIKey||MWLSOWXNZPKENC-UHFFFAOYSA-N|
|Search Google for chemicals with the same backbone||MWLSOWXNZPKENC|
|Search PubMed clinical trials||zileuton|
|Search PubMed titles||zileuton|
|Search PubMed titles/abstracts||zileuton|
|Search UniChem for chemical match using the InChIKey||MWLSOWXNZPKENC-UHFFFAOYSA-N|
|Search UniChem for chemicals with the same backbone||MWLSOWXNZPKENC|
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.✖
Cat. No. 3308